Work

123MO Monalizumab, cetuximab and durvalumab in first-line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): A phase II trial

Year: 2021

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2021.10.142

Authors: D.A. Colevas, K. Misiukiewicz, A.T. Pearson, J. Fayette, J.R. Bauman, D. Cupissol, E. Saada-Bouzid, D.R. Adkins, D.B. Marie, S.L. Cornen, P. André, F. Carrette, F. Rotolo, A. Boyer Chammard, R.B. Cohen

Institutions: Stanford Medicine, Stanford University, Mount Sinai Hospital, University of Chicago, Centre Léon Bérard, Fox Chase Cancer Center, Institut Regional du Cancer de Montpellier, Centre Antoine Lacassagne, Washington University in St. Louis, Innate Pharma (France), Abramson Cancer Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4200219012

FWCI: 0.988

Cites:

Cited by: 12

Related to: 10